Dean Rick Schnellmann, PhD, shared with Provost Prelock and President Garimella his decision to step down, effective June 30, 2025. He will return to his tenured faculty position in the Department of Pharmacology and Toxicology after a one-year research leave before resuming research in July 2026.Continue reading
Category Archives: AZBio News
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
Gold-level Stevie® Award recognizes Maetzold’s transformative leadership in the healthcare industry, including molecular diagnostics and precision medicine
“Derek’s vision and unwavering commitment to improving patient care have been the driving force behind Castle Biosciences’ remarkable success story,”Continue reading
Applications are open for the new IMPACT Masters Program at ASU
Imagine the IMPACT of a Biodesign program at the intersection of the #1 most innovative university (Arizona State University) and the #1 hospital in the world (Mayo Clinic)…Continue reading
ASU to help target how cancer evades treatment
Up to $142M in funding announced for research group that includes MIT and StanfordContinue reading
In memoriam: Linda Hunt
Linda Ann St. Pierre Hunt passed away very peacefully on May 17, 2025 at Sherman Home, Hospice of the Valley in Phoenix with her brother Raymond St. Pierre by her side. Linda courageously battled cancer for the past few years as well as other health-related challenges.Continue reading
Whole-Person Genomics: New Partnership Tackles Rare Disease and Serious Mental Illness by Linking DNA Insights with Community Social Support Networks
TUCSON, AZ – UGenome AI, a pioneer in genomic technology, today announced an expanded partnership with Jura Health, Inc. to integrate both pharmacogenomic and nutrigenomic insights into the diagnosis of rare diseases and the development of personalized care plans. By combining expertise in whole genome sequencing (WGS), drug-gene interactions, and nutrient- gene relationships, the collaboration is designed to help rare disease patients receive earlier diagnoses, safer treatments, and lifestyle guidance tailored to their DNA.Continue reading
Critical Path Institute and Citizen Health Partner to Accelerate Drug Development for Neuromuscular Disorders
SAN FRANCISCO and TUCSON, Ariz., May 29, 2025 — Critical Path Institute® (C-Path), a global nonprofit accelerating drug development through data science and regulatory innovation, and Citizen Health, a leading consumer health platform, today announced their new strategic collaboration. Together, the organizations will establish a partnership focused on neuromuscular disorders, including limb-girdle muscular dystrophies (LGMDs), Charcot-Marie-Tooth (CMT) disease, nemaline myopathy (NM), myotonic dystrophies, and related conditions.Continue reading
CEO Forums: An FDA Listening Tour to Engage Pharma CEOs
The U.S. Food and Drug Administration is conducting a national listening tour to meet directly with pharmaceutical and biotech CEOs. Held in major innovation hubs across the country, the CEO Forums will be led by FDA Commissioner Marty A. Makary, M.D., M.P.H., along with Principal Deputy Commissioner Sara Brenner, M.D., M.P.H and Director of FDA’s Center for Biologics Evaluation and Research, Vinay Prasad, M.D., M.P.H.Continue reading
ASU partners with biotech luminary and alum Mark McKenna to launch preeminent life science business program
- Future health care leaders and innovators will accelerate their path through the McKenna Life Sciences, Business and Entrepreneurship Program, enabling the next generation of biotech game changers.
- A cross-college collaboration between the W. P. Carey School of Business and The College of Liberal Arts and Sciences, the program reflects ASU’s decade-long status as America’s most innovative university.
- The program will launch in 2026 through a generous gift from Mark and Sheri McKenna.
Drug discovery startup based on UA research receives $4 million seed funding
The preclinical stage company was founded to commercialize drugs to treat multiple cancers.Continue reading